David H Aggen
Overview
Explore the profile of David H Aggen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim K, Alam S, Kuo F, Chen Z, Yip W, Katims A, et al.
Eur Urol
. 2024 Nov;
87(3):342-354.
PMID: 39550333
Background And Objective: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed...
2.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 Oct;
87(1):96.
PMID: 39426859
No abstract available.
3.
Dallos M, Obradovic A, McCann P, Chowdhury N, Pratapa A, Aggen D, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5218-5230.
PMID: 39269310
Purpose: Androgen deprivation therapy (ADT) remains the backbone of prostate cancer treatment. Beyond the suppression of testosterone and tumor cell growth, emerging evidence suggests that ADT also modulates the immune...
4.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 May;
86(2):90-94.
PMID: 38782695
Treatment options are limited for patients with non-clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib...
5.
Aggen D, Rosenberg J
Nat Rev Clin Oncol
. 2024 Apr;
21(7):487-488.
PMID: 38622410
No abstract available.
6.
Kotecha R, Doshi S, Knezevic A, Chaim J, Chen Y, Jacobi R, et al.
Eur Urol Oncol
. 2023 Nov;
7(4):804-811.
PMID: 37945488
Background: Although different kidney cancers represent a heterogeneous group of malignancies, multiple subtypes including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient...
7.
Guercio B, Sarfaty M, Teo M, Ratna N, Duzgol C, Funt S, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4586-4595.
PMID: 37682528
Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered urothelial carcinoma and real-world clinical outcomes with erdafitinib, including on-treatment...
8.
Aggen D, Chu C, Rosenberg J
Clin Cancer Res
. 2023 Feb;
29(8):1377-1380.
PMID: 36749325
Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low...
9.
Fitzgerald K, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen D, et al.
Eur Urol
. 2022 Nov;
83(3):195-199.
PMID: 36344318
Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and nivolumab (IO/IO) and several combinations of vascular endothelial growth...
10.
Obradovic A, Chowdhury N, Haake S, Ager C, Wang V, Vlahos L, et al.
Cell
. 2021 May;
184(11):2988-3005.e16.
PMID: 34019793
Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) atlas, we performed single-cell RNA sequencing (scRNA-seq) of...